BIGG Rec Logo
BIGG Rec Logo
Guideline

Abortion care guideline

Year of Publication
2022
Issuing Institution
WHO
Links
WHO IRIS,Pubmed

Recommendations

105 included recommendations

For medical management of intrauterine fetal demise (IUFD) at ≥ 14 to ≤ 28 weeks: Suggest the use of combination mifepristone plus misoprostol over misoprostol alone; Suggested regimen: 200 mg mifepristone administered orally, followed 1–2 days later by repeat doses of 400 μg misoprostol administered sublingually or vaginally every 4–6 hours. The minimum recommended interval between use of mifepristone and misoprostol is 24 hours; Alternative regimens: repeat doses of 400 μg misoprostol administered sublingually or vaginally every 4–6 hours.

Status
Maintained

Recommended in favor

Conditional

For individuals undergoing medical abortion with the combination mifepristone and misoprostol regimen or with misoprostol alone: For those who choose to use hormonal contraception (oral contraceptive pills, contraceptive patch, contraceptive ring, contraceptive implant or contraceptive injections): Suggest that they be given the option of starting hormonal contraception immediately after the first pill of the medical abortion regimen

Status
Maintained

Recommended in favor

Conditional

For medical abortion at < 12 weeks (using the combination of mifepristone plus misoprostol or using misoprostol alone): Recommend the option of self-management of the medical abortion process in whole or any of the three component parts of the process: self-assessment of eligibility (determining pregnancy duration; ruling out contraindications); self-administration of abortion medicines outside of a health-care facility and without the direct supervision of a trained health worker, and management of the abortion process; self-assessment of the success of the abortion

Status
Maintained

Recommended in favor

Strong

Powered byEpistemonikos Foundation